Baxter Stock Plunges 7%, Wiping Out $962 Million, Despite Raised 2026 Outlook
Adjusted profit per share fell on a higher tax rate, and Baxter said it will stop making cephalosporin drugs at its Round Lake plant.
Baxter International shares fell 7.31% to $23.60 in Thursday trading, as of 1:30 p.m. ET, erasing $962 million in market value, the day after the company lifted its 2026 outlook while reporting that third-quarter adjusted earnings per share fell from a year earlier on a higher tax rate.
Revenue up, adjusted profit down
Baxter reported third-quarter adjusted earnings of 58 cents a share, down from 69 cents a year earlier. Revenue rose to $2.98 billion from $2.84 billion.
The company now expects full-year adjusted earnings of $2.05 to $2.15 a share, up from a prior range of $1.95 to $2.15. Third-quarter free cash flow was $448 million, the company said, as it completed a tender offer to reduce debt.
On the earnings call, management said Baxter will stop making cephalosporin drugs at its Round Lake plant, giving up $30 million of 2026 operating income. The call linked the exit to an FDA warning letter.
Giving back a 33% run
Baxter makes healthcare products, including IV solutions, infusion systems, generic injectable drugs and respiratory devices, for hospitals, nursing homes, dialysis centers and patients at home. It reports three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
The stock was up about 33% year to date as of Wednesday's close, against about 13% for the S&P 500. Thursday's drop put it on pace for its biggest one-day fall since February 12, when it dropped 16.0%.
CEO Andrew Hider said on the call that a competitor's supply trouble was "not a small piece" of double-digit growth in the Advanced Surgery unit, and warned of tougher comparisons ahead.
Hider's warning of tougher comparisons in Advanced Surgery came on the same call that raised the full-year range.
Sources
- Baxter Non-GAAP EPS of $0.58 beats by $0.06, revenue of $2.98B beats by $70M (NYSE:BAX) | Seeking Alpha — seekingalpha.com
- Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised — Yahoo Finance
- Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates — Yahoo Finance
- Baxter: Q3 Earnings Snapshot — Associated Press
- Baxter Intl Q3 2026 Earnings Call Transcript — benzinga.com
- The company's filing (Baxter International) — SEC filing
- Baxter International — Form 10-Q for the quarter ended 2026-06-30 (quarterly results) — SEC EDGAR